ライフサイエンスコーパス: schizoaffective

1 sychosis, clinical or genetic high risk, and schizoaffective.

2 ive predictive value=83%) but much lower for schizoaffective and atypical psychoses.

3 We identified cases of schizophrenia, schizoaffective and bipolar disorder aged >/= 15 years i

4 ount for predisposition to schizophrenia and schizoaffective and bipolar disorder and failure to dete

5 with the highest reported frequencies in the schizoaffective and bipolar groups.

6 is of combined mixed-ancestry schizophrenia, schizoaffective, and bipolar cohorts that resulted in th

7 whether operationally defined schizophrenic, schizoaffective, and manic syndromes share genetic risk

8 the genes contributing to RDC schizophrenic, schizoaffective, and manic syndromes.

9 irings of schizophrenic-manic, schizophrenic-schizoaffective, and schizoaffective-manic syndromes bot

10 bipolar I disorder and 274 schizophrenia or schizoaffective Ashkenazi case-parent trios.

11 ined through sibling pairs with bipolar I or schizoaffective bipolar disorder.

12 nd adequate social/vocational functioning; a schizoaffective diagnosis predicted symptom remission.

13 s not observed, which casts further doubt on schizoaffective diagnosis.

14 ere psychosis not otherwise specified (44%), schizoaffective disorder (36%), and brief psychosis (27%

15 a (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to

16 Cases with diagnoses of schizophrenia or schizoaffective disorder (DSM-IIIR criteria) were consid

17 henotypes for probands with schizophrenia or schizoaffective disorder (extensive neocortical or subco

18 y greater from bipolar disorder (z=-0.77) to schizoaffective disorder (manic z=-1.08; depressed z=-1.

19 (N=293), psychotic bipolar disorder (N=227), schizoaffective disorder (manic, N=110; depressed, N=55)

20 outpatients diagnosed with schizophrenia or schizoaffective disorder (mean [SD] age, 46 [11] years;

21 7); schizophrenia, simple schizophrenia, and schizoaffective disorder (n = 178); and all nonaffective

22 eting criteria for schizophrenia (n = 19) or schizoaffective disorder (n = 7) and 26 healthy controls

23 s in their first episode of schizophrenia or schizoaffective disorder (N=118) were assessed at baseli

24 cording to DSM-IV as having schizophrenia or schizoaffective disorder (N=155), bipolar disorder with

25 nth follow-up to patients with schizophrenia/schizoaffective disorder (N=225), bipolar disorder with

26 e offspring of mothers with schizophrenia or schizoaffective disorder (N=26) and matched comparison m

27 ed for nonpsychotic bipolar disorder (N=68), schizoaffective disorder (N=31), or schizophrenia (N=536

28 Adults with schizophrenia or schizoaffective disorder (N=481) were randomly assigned

29 icated patients with schizophrenia (N=61) or schizoaffective disorder (N=6).

30 ection sites, patients with schizophrenia or schizoaffective disorder (N=610), their biological relat

31 morbidity, and diagnosis of schizophrenia or schizoaffective disorder (p<0.01 for all contrasts).

32 r disorder (RR, 0.42; 95% CI, 0.17-0.69) and schizoaffective disorder (RR, 0.44; 95% CI, 0.11-0.79) c

33 a superimposed mood syndrome [SZ+; N = 224], schizoaffective disorder [SAD; N = 129] and bipolar I di

34 s: (1) 170 individuals with schizophrenia or schizoaffective disorder and (2) 84 patients with broad

35 A total of 18 treatment studies of schizoaffective disorder and 15 of schizophrenia with mo

36 out including 10,925 cases with BPAD, SZ, or schizoaffective disorder and 16,747 controls.

37 Eighteen individuals with schizophrenia or schizoaffective disorder and 19 healthy control particip

38 nsisted of 23 patients with schizophrenia or schizoaffective disorder and 19 non-psychiatric voluntee

39 nts in the first episode of schizophrenia or schizoaffective disorder and 22 healthy comparison subje

40 Twenty-seven patients with schizophrenia or schizoaffective disorder and 23 healthy controls.

41 In 24 patients with schizophrenia or schizoaffective disorder and 25 healthy comparison subje

42 with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder and 26 healthy volunteers parti

43 ata for 3,945 subjects with schizophrenia or schizoaffective disorder and 3,611 screened comparison s

44 tudied 127 outpatients with schizophrenia or schizoaffective disorder and 30 healthy comparison subje

45 relates in 33 patients with schizophrenia or schizoaffective disorder and 31 healthy comparison subje

46 Forty-four patients with schizophrenia or schizoaffective disorder and 34 healthy comparison subje

47 ged and older patients with schizophrenia or schizoaffective disorder and 38 normal comparison subjec

48 essed in 149 consumers with schizophrenia or schizoaffective disorder and 50 healthy control subjects

49 ort of 524 individuals with schizophrenia or schizoaffective disorder and 573 control subjects.

50 ction from 62 subjects with schizophrenia or schizoaffective disorder and 62 matched healthy comparis

51 a subset of 59 people with schizophrenia or schizoaffective disorder and 65 healthy controls, and pr

52 dication-free patients with schizophrenia or schizoaffective disorder and 74 healthy comparison indiv

53 btained from 96 people with schizophrenia or schizoaffective disorder and 83 healthy controls.

54 , 18-51 years; 59 men) with schizophrenia or schizoaffective disorder and 87 healthy controls (mean [

55 0) sibling pair studies of schizophrenia and schizoaffective disorder and a comparable study of bipol

56 psychiatric disorders, mainly schizophrenia, schizoaffective disorder and bipolar disorder.

57 individuals diagnosed with schizophrenia or schizoaffective disorder and in 197 healthy comparison s

58 individuals diagnosed with schizophrenia or schizoaffective disorder and in 197 healthy comparison s

59 men comorbid for DSM-III-R schizophrenia or schizoaffective disorder and lifetime alcohol abuse or d

60 d lifetime rates were found in patients with schizoaffective disorder and major depression with psych

61 ants included 56 women with schizophrenia or schizoaffective disorder and marked symptom severity des

62 ction from 36 subjects with schizophrenia or schizoaffective disorder and matched normal comparison s

63 Twenty-four patients with schizophrenia or schizoaffective disorder and medication-resistant AHs we

64 atients with first-episode schizophrenia and schizoaffective disorder and potential predictors of res

65 who met DSM-IV criteria for schizophrenia or schizoaffective disorder and retrospective and prospecti

66 A boundary between schizoaffective disorder and schizophrenia was not obser

67 h diagnoses of bipolar disorder, depression, schizoaffective disorder and schizophrenia).

68 viduals with DSM-IV-defined schizophrenia or schizoaffective disorder and their mothers underwent a 4

69 o overlapping groups of patients: those with schizoaffective disorder and those with schizophrenia an

70 Affairs (VA) system who had schizophrenia or schizoaffective disorder and who had been hospitalized w

71 nsider 166 persons who have schizophrenia or schizoaffective disorder and who have had either their g

72 nergic mechanisms to treat schizophrenia and schizoaffective disorder appears indicated.

73 Established nosology identifies schizoaffective disorder as a distinct category with bou

74 assess the rationale for the continuation of schizoaffective disorder as a legitimate diagnostic cate

75 were diagnosed with either schizophrenia or schizoaffective disorder as defined by the DSM-IV.

76 me, however, have questioned the validity of schizoaffective disorder as separate from psychotic mood

77 attempts in patients with schizophrenia and schizoaffective disorder at high risk for suicide.

78 mately 50% of patients with schizophrenia or schizoaffective disorder attempt suicide, and approximat

79 RNA levels were 13.6% lower in subjects with schizoaffective disorder but did not differ in subjects

80 dysregulation of calreticulin homeostasis in schizoaffective disorder by both genetic and functional

81 SZ: OR = 2.40, p = 1.3 x 10(-4); SZ, BD, and schizoaffective disorder combined: OR = 1.87, p = 8 x 10

82 Twenty-six patients with schizophrenia and schizoaffective disorder completed a task requiring alte

83 The diagnosis of schizoaffective disorder depends on the disease specific

84 hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blin

85 The patients with schizophrenia or schizoaffective disorder exhibited less accuracy and spe

86 The schizophrenia or schizoaffective disorder group exhibited decreased power

87 The schizoaffective disorder group was split, with six subje

88 the schizophrenia, simple schizophrenia, and schizoaffective disorder group were inversely related (b

89 The diagnosis of schizoaffective disorder has long maintained an uncertai

90 n this mutation in the calreticulin gene and schizoaffective disorder has remained speculative.

91 ents with clinically stable schizophrenia or schizoaffective disorder have a lower risk of relapse if

92 atients with first-episode schizophrenia and schizoaffective disorder have high rates of response to

93 However, because most prior studies of schizoaffective disorder have only evaluated differences

94 2q11 microdeletions develop schizophrenia or schizoaffective disorder in adolescence and adulthood.

95 iated with the diagnosis of schizophrenia or schizoaffective disorder in the white subset of the stud

96 revious studies, these findings suggest that schizoaffective disorder is associated with lower levels

97 uggest that negative affect in schizophrenia/schizoaffective disorder is associated-directly or indir

98 s of rarity between them and suggesting that schizoaffective disorder is not a separate, 'bona-fide'

99 r, the interrater reliability for diagnosing schizoaffective disorder is very low.

100 Patients diagnosed with schizoaffective disorder likely suffer from a psychotic

101 Contrary to earlier formulations, schizoaffective disorder may be a more severe form of il

102 that hippocampal volume in schizophrenia or schizoaffective disorder may be linked to time of diseas

103 These results suggest that schizoaffective disorder may possess distinct features.

104 Furthermore, patients with a diagnosis of schizoaffective disorder or a history of at least one ma

105 t of other variables, such as a diagnosis of schizoaffective disorder or medication use at the time o

106 For acute exacerbations of schizoaffective disorder or of schizophrenia with mood s

107 ht outpatients with chronic schizophrenia or schizoaffective disorder over 16 weeks.

108 One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, doub

109 tivity (rsfMRI) approach in 84 schizophrenia/schizoaffective disorder patients and 66 healthy compari

110 positive psychotic symptoms in schizophrenia/schizoaffective disorder patients at 24 months suggests

111 ed (125 SZ, 120 bipolar disorder [BD] and 36 schizoaffective disorder patients vs. 467 unaffected adu

112 than the other two groups, and schizophrenia/schizoaffective disorder patients with baseline panic sy

113 Finally, within the schizophrenic/schizoaffective disorder patients, smaller hippocampal v

114 Subjects with schizoaffective disorder performed significantly worse t

115 SZ probands, n = 224; PBD probands, n = 190; schizoaffective disorder probands, n = 142; unaffected r

116 ome among outpatients with schizophrenia and schizoaffective disorder receiving clozapine with a matc

117 ple of 162 outpatients with schizophrenia or schizoaffective disorder recruited from four sites.

118 generally better preserved in patients with schizoaffective disorder relative to patients with schiz

119 relatives, n = 195; PBD relatives, n = 175; schizoaffective disorder relatives, n = 113]; control su

120 present or present to a lesser degree in the schizoaffective disorder subjects (diagnosis of schizoaf

121 iously reported linkage of schizophrenia and schizoaffective disorder to 13q32-34 in the European des

122 cal and biological features of patients with schizoaffective disorder to patients with related disord

123 able condition with chronic schizophrenia or schizoaffective disorder to receive treatment with flexi

124 we have also found linkage of schizophrenia/schizoaffective disorder to this same chromosomal region

125 patients with early-onset schizophrenia and schizoaffective disorder to treatment with either olanza

126 Schizoaffective disorder unifies schizophrenia and bipol

127 Schizoaffective disorder was associated with low emotion

128 for the phenotype of DSM-IV schizophrenia or schizoaffective disorder was found in a region on chromo

129 Schizoaffective disorder was named as a compromise diagn

130 izoaffective disorder subjects (diagnosis of schizoaffective disorder was the most significant covari

131 rty-three outpatients with schizophrenia and schizoaffective disorder were categorized into deficit a

132 schizophrenia, schizophreniform disorder, or schizoaffective disorder were evaluated during their fir

133 Thirty patients with schizophrenia or schizoaffective disorder were investigated.

134 The characteristics of schizoaffective disorder were more often similar to schi

135 mRNA and protein levels within subjects with schizoaffective disorder were not attributable to factor

136 y-five patients with DSM-IV schizophrenia or schizoaffective disorder were randomly assigned for 9 mo

137 Sixty-nine people with schizophrenia or schizoaffective disorder were randomly assigned to 36 se

138 Sixty-five patients with schizophrenia or schizoaffective disorder were randomly assigned to NET p

139 who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to recei

140 outpatients with DSM-III-R schizophrenia or schizoaffective disorder were randomly assigned to recei

141 Fifty outpatients with schizophrenia or schizoaffective disorder were randomly assigned to recei

142 7) outpatients with chronic schizophrenia or schizoaffective disorder were randomly assigned to recei

143 lly stable outpatients with schizophrenia or schizoaffective disorder were randomly assigned to train

144 total of 181 patients with schizophrenia or schizoaffective disorder were recruited from three clini

145 SFs of the individuals with schizophrenia or schizoaffective disorder were related to those of the hu

146 n) with DSM-IV diagnoses of schizophrenia or schizoaffective disorder were selected to form two group

147 ia for treatment-refractory schizophrenia or schizoaffective disorder were studied.

148 cing their first episode of schizophrenia or schizoaffective disorder were treated first with clozapi

149 tics of 52 individuals with schizophrenia or schizoaffective disorder who had attempted suicide with

150 ose of 104 individuals with schizophrenia or schizoaffective disorder who had not made a suicide atte

151 tients meeting criteria for schizophrenia or schizoaffective disorder who had residual symptoms despi

152 cessation in patients with schizophrenia or schizoaffective disorder who were also treated with the

153 were adults diagnosed with schizophrenia or schizoaffective disorder who were clinically assessed to

154 lve patients with DSM-IV bipolar disorder or schizoaffective disorder who were clinically stable whil

155 cing their first episode of schizophrenia or schizoaffective disorder who were given fluphenazine as

156 treatment in patients with schizophrenia and schizoaffective disorder who were hospitalized or at hig

157 d fifty-seven patients with schizophrenia or schizoaffective disorder who were inpatients at four hos

158 ly assaultive subjects with schizophrenia or schizoaffective disorder who were inpatients in state ps

159 Thirty patients with schizophrenia or schizoaffective disorder who were receiving clozapine mo

160 Patients with schizophrenia or schizoaffective disorder with a body mass index >/= 27 a

161 ded schizophrenia, simple schizophrenia, and schizoaffective disorder with poor outcome.

162 severity continuum (schizophrenia worse than schizoaffective disorder worse than bipolar psychosis);

163 mple included 1,870 cases (schizophrenia and schizoaffective disorder) and 2,002 screened comparison

164 SZ (including a subgroup diagnosed as having schizoaffective disorder) and 26 age-matched and sex-mat

165 in a live cohort of psychosis (schizophrenia/schizoaffective disorder) subjects.

166 sensus diagnosis of schizophrenia (including schizoaffective disorder) using DSM-III or DSM-IV criter

167 e (as a part of major depressive disorder or schizoaffective disorder) were at a greater risk for sui

168 spectrum disorders (mostly schizophrenia and schizoaffective disorder) who had available second-trime

169 re mental illness (46% with schizophrenia or schizoaffective disorder) who had not obtained or kept c

170 probands (63 with schizophrenia and 12 with schizoaffective disorder), ascertained so as to be repre

171 arrow phenotype psychosis (schizophrenia and schizoaffective disorder), broad psychosis, and control

172 esponse were diagnosis (schizophrenia versus schizoaffective disorder), premorbid functioning, durati

173 spectrum disorders (mostly schizophrenia and schizoaffective disorder).

174 spectrum disorders (mostly schizophrenia and schizoaffective disorder).

175 d group of 21 subjects with schizophrenia or schizoaffective disorder, 11 subjects with schizotypal p

176 randomization, 58.1% had schizophrenia or a schizoaffective disorder, 22.0% had bipolar disorder, an

177 ducted in 980 patients with schizophrenia or schizoaffective disorder, 26.8% of whom were refractory

178 reviously reported): 19 patients with SCZ or schizoaffective disorder, 30 unaffected first-degree rel

179 g pairs with a diagnosis of schizophrenia or schizoaffective disorder, 396 highly polymorphic markers

180 comprising 42 patients with schizophrenia or schizoaffective disorder, 57 of their unaffected first-d

181 bipolar disorder with psychotic features, or schizoaffective disorder, and 10,195 population control

182 h psychosis (146 with schizophrenia, 90 with schizoaffective disorder, and 115 with psychotic bipolar

183 with schizophrenia, 106 of individuals with schizoaffective disorder, and 129 of individuals with ps

184 tients with schizophrenia, 103 patients with schizoaffective disorder, and 129 patients with psychoti

185 nts met DSM-IV criteria for schizophrenia or schizoaffective disorder, and 21 nonpsychiatric voluntee

186 atients with schizophrenia, 32 patients with schizoaffective disorder, and 40 patients with bipolar d

187 ely 65% of participants had schizophrenia or schizoaffective disorder, and 85.5% were receiving conco

188 Schizophrenia, schizoaffective disorder, and bipolar disorder are commo

189 collected on individuals with schizophrenia, schizoaffective disorder, and bipolar disorder with psyc

190 nd exon 9 are associated with schizophrenia, schizoaffective disorder, and bipolar disorder.

191 nical phenotype of psychosis (schizophrenia, schizoaffective disorder, and bipolar I disorder with ps

192 People with schizophrenia, schizoaffective disorder, and bipolar illness share clin

193 Heritability estimates for schizophrenia, schizoaffective disorder, and mania were substantial and

194 sychotic disorders (including schizophrenia, schizoaffective disorder, and psychotic bipolar disorder

195 bipolar I, bipolar II with major depression, schizoaffective disorder, and recurrent unipolar disorde

196 bipolar disorder, major depressive disorder, schizoaffective disorder, and schizophrenia) in male par

197 probands (60 with schizophrenia and 12 with schizoaffective disorder, ascertained so as to be repres

198 meeting DSM-IV criteria for schizophrenia or schizoaffective disorder, assessed during acute admissio

199 and three psychotic disorders--schizophrenia/schizoaffective disorder, bipolar disorder with psychosi

200 ss as a clinical diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or other psy

201 9), bipolar disorder (DSM-IV-TR) (N=40), and schizoaffective disorder, bipolar type (N=18).

202 probands with bipolar I disorder (N=192) and schizoaffective disorder, bipolar type, (N=11) were incl

203 bipolar I disorder; bipolar II disorder; or schizoaffective disorder, bipolar type, according to DSM

204 ion to antipsychotic action in patients with schizoaffective disorder, bipolar type, and bipolar I di

205 nd bipolar disorder and parses patients with schizoaffective disorder, bipolar type, into two subgrou

206 d aim was to determine whether subjects with schizoaffective disorder, bipolar type, were neurophysio

207 ive disorder and a sibling with bipolar I or schizoaffective disorder, bipolar type.

208 is of a major affective disorder (BP type I; schizoaffective disorder, bipolar type; BP type II; or m

209 models (ASMs) were considered: ASM1 (BPI and schizoaffective disorder, BP cases (SABP) only), ASM2 (A

210 and in patients with schizophrenia (N=12) or schizoaffective disorder, depressed type (N=4), during a

211 nostic Criteria major depressive disorder or schizoaffective disorder, depressed type, entered a long

212 atients with a diagnosis of schizophrenia or schizoaffective disorder, depressed type.

213 Research Diagnostic Criteria schizophrenia, schizoaffective disorder, mania, DSM-III-R schizophrenia

214 -six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and

215 In the subjects with schizoaffective disorder, mean GAD65 protein levels were

216 psychotic disorders (schizophrenia, n = 219; schizoaffective disorder, n = 142; and psychotic bipolar

217 7 schizophrenia cases (schizophrenia, N=630; schizoaffective disorder, N=147) with maternal sera avai

218 trial included patients with schizophrenia, schizoaffective disorder, or a mood disorder who had mod

219 d first-degree relatives with schizophrenia, schizoaffective disorder, or bipolar disorder.

220 nths; a clinical diagnosis of schizophrenia, schizoaffective disorder, or delusional disorder; and a

221 participants with underlying schizophrenia, schizoaffective disorder, or mood disorder.

222 of patients hospitalized for schizophrenia, schizoaffective disorder, or nonpsychotic bipolar disord

223 1239 cases with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder;

224 ited 933 stable probands with schizophrenia, schizoaffective disorder, or psychotic bipolar I disorde

225 ients with a first episode of schizophrenia, schizoaffective disorder, or schizophreniform disorder (

226 had a DSM-III-R diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder a

227 who were later diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder,

228 riptome signatures are not characteristic of schizoaffective disorder, providing a potential molecula

229 netic, reveals multiple similarities between schizoaffective disorder, schizophrenia and psychotic bi

230 Inpatient diagnoses of bipolar disorder, schizoaffective disorder, schizophrenia, and other nonaf

231 In adults with schizophrenia or schizoaffective disorder, use of paliperidone palmitate

232 ved a research diagnosis of schizophrenia or schizoaffective disorder, whereas 44% of patients with n

233 The diagnosis of schizoaffective disorder, which can result in substandar

234 ht outpatients with chronic schizophrenia or schizoaffective disorder.

235 h analysis of 4084 samples with BPAD, SZ, or schizoaffective disorder.

236 and cognitive functions in schizophrenia and schizoaffective disorder.

237 asive nicotinic effects in schizophrenia and schizoaffective disorder.

238 ican American probands with schizophrenia or schizoaffective disorder.

239 r predisposition genes for schizophrenia and schizoaffective disorder.

240 e treatment of early-onset schizophrenia and schizoaffective disorder.

241 e for treating early-onset schizophrenia and schizoaffective disorder.

242 olescents with early-onset schizophrenia and schizoaffective disorder.

243 up (68% of survivors); 175 had schizophrenia/schizoaffective disorder.

244 otics to treat early-onset schizophrenia and schizoaffective disorder.

245 tpatients with diagnoses of schizophrenia or schizoaffective disorder.

246 age and older patients with schizophrenia or schizoaffective disorder.

247 ficacy in the treatment of schizophrenia and schizoaffective disorder.

248 e intron 1/exon 2 region in individuals with schizoaffective disorder.

249 acutely ill inpatients with schizophrenia or schizoaffective disorder.

250 tion of the exon 9 missense allele Phe607 in schizoaffective disorder.

251 patients with diagnoses of schizophrenia or schizoaffective disorder.

252 ent of the first episode of schizophrenia or schizoaffective disorder.

253 with acute exacerbation of schizophrenia or schizoaffective disorder.

254 e and negative symptoms in schizophrenia and schizoaffective disorder.

255 nt of patients with chronic schizophrenia or schizoaffective disorder.

256 f relapse in patients with schizophrenia and schizoaffective disorder.

257 dividuals with recent-onset schizophrenia or schizoaffective disorder.

258 cognition in patients with schizophrenia or schizoaffective disorder.

259 ords of 82 outpatients with schizophrenia or schizoaffective disorder.

260 ume was found in patients with schizophrenia/schizoaffective disorder.

261 ponse to a first episode of schizophrenia or schizoaffective disorder.

262 ry from a first episode of schizophrenia and schizoaffective disorder.

263 a major depressive episode or diagnosed with schizoaffective disorder.

264 behavior in patients with schizophrenia and schizoaffective disorder.

265 sfunction in patients with schizophrenia and schizoaffective disorder.

266 ressive disorder (MDD), bipolar disorder, or schizoaffective disorder.

267 years of age or older with schizophrenia or schizoaffective disorder.

268 he abnormalities were similar between SZ and schizoaffective disorder.

269 ohort, 4310 developed bipolar disorder; 784, schizoaffective disorder; 4823, schizophrenia; and 5013,

270 .5% met DSM-IV criteria for schizophrenia or schizoaffective disorder; 55.8%, for major affective dis

271 ence; 64 men with DSM-III-R schizophrenia or schizoaffective disorder; 62 men with Research Diagnosti

272 samples (528 UK patients with schizophrenia/schizoaffective disorder; 921 German participants includ

273 ID1) met this criterion for schizophrenia or schizoaffective disorder; five replicate previous associ

274 (SZ), psychotic bipolar disorder (PBD), and schizoaffective disorder; their first-degree relatives;

275 al regions were limited to schizophrenia and schizoaffective disorders (P < .001).

276 Bipolar, schizophrenia, and schizoaffective disorders are common, highly heritable p

277 Individuals with schizophrenia or schizoaffective disorders were included as cases.

278 ntal illness (defined here as schizophrenia, schizoaffective disorders, and bipolar affective disorde

279 hotic disorders, including schizophrenia and schizoaffective disorders.

280 s significantly higher for the patients with schizoaffective illness than for those with bipolar diso

281 hium and experiencing an episode of mania or schizoaffective mania diagnosed according to Research Di

282 ated probands with bipolar I, bipolar II, or schizoaffective-manic disorder and 63 comparison subject

283 ic-manic, schizophrenic-schizoaffective, and schizoaffective-manic syndromes both within probands and

284 ght patients meeting the DSM-IV criteria for schizoaffective or bipolar disorder that was deemed trea

285 teria (RDC) for lifetime-ever schizophrenic, schizoaffective, or manic syndrome were ascertained from

286 brain were obtained for 64 schizophrenic or schizoaffective patients (representative of all such pro

287 Fourteen stable, medicated schizophrenia/schizoaffective patients and 13 healthy comparison subje

288 was assessed in a cohort of 40 schizophrenia/schizoaffective patients relative to 42 healthy control

289 Schizophrenia/schizoaffective patients show highly significant deficit

290 s were NCT01474395/NCT02156908 Schizophrenia/schizoaffective patients showed significantly reduced au

291 tidepressant treatment for schizophrenic and schizoaffective patients who develop a major depressive

292 In a second cohort (n = 21 schizophrenia/schizoaffective patients, n = 13 healthy controls), even

293 Across DSM-IV diagnoses, schizophrenia and schizoaffective probands showed overlapping gray matter

294 Schizophrenia and schizoaffective probands versus healthy controls showed

295 risk for recurrent unipolar (RUP), BIP, and schizoaffective (SA) disorders, while relatives of schiz

296 .4 for rs722642 at 78 cM) using only BPI and schizoaffective (SA), BP cases.

297 pectrum of mood disorders (that is, bipolar, schizoaffective (SAF), major depression) based on contem

298 syndromes, but the genetic liability to the schizoaffective syndrome was entirely shared in common w

299 In contrast, environmental liability to the schizoaffective syndrome was not shared with the other s

300 nia, and are scant for psychotic bipolar and schizoaffective (SZA) disorders and for relatives of the